The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck

Future Oncology

Volumn 1, Issue 1, 2005, Pages 115-123

  Norris, James S ^a   Norris, Kristi L ^b   Holman, David H ^a   El Zawahry, Ahmed ^a   Keane, Thomas E ^a   Dong, Jian Yun ^a   Tavassoli, Mahvash ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acid ceramidase; Adenoviral mediated p53 gene therapy; Apoptosis; Ceramide; Fas ligand; Gene therapy; ONYX 015; Probasin Newcastle disease virus; Prostate cancer; Prostatespecific antigen; Replication competent adenovirus; Sphingolipids; Squamous cell cancer of the head and neck

Indexed keywords

ACYLSPHINGOSINE DEACYLASE; AMIDASE; CERAMIDE; CYTOSINE DEAMINASE; FAS LIGAND; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; ONYX 015; THYMIDINE KINASE; TUMOR NECROSIS FACTOR;

ADENOVIRUS; DRUG ANTAGONISM; GENE THERAPY; GENETICS; HEAD AND NECK TUMOR; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; AMIDOHYDROLASES; CARCINOMA, SQUAMOUS CELL; CERAMIDES; CYTOSINE DEAMINASE; FAS LIGAND PROTEIN; GENE THERAPY; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; PROSTATIC NEOPLASMS; THYMIDINE KINASE; TUMOR NECROSIS FACTORS;

EID: 85047689323     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.1517/14796694.1.1.115     Document Type: Review

References (64)

1. Evan GI, Vousden, KH: Proliferation, cell cycle and apoptosis in cancer. Nature 411(6835) 342-348 (2001).
2. Ko LJ, Prives C: p53: puzzle and paradigm. Genes Dev. 10(9), 1054-1072 (1996).
3. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88(3), 323-331 (1997).
4. Morgan SE, Lovly C, Pandita TK, Shiloh Y, Kastan MB: Fragments of ATM which have dominant-negative or complementing activity. Mol. Cell. Biol. 17(4), 2020-2029 (1997).
5. Blons H, Laurent-Puig P: TP53 and head and neck neoplasms. Hum. Mutat. 21(3), 252-257 (2003).
6. Boyle JO, Hakim J, Koch W et al.: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 53(19), 4477-4480 (1993).
7. Brooks J, Bova G, Ewing C et al.: An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res. 56(16) 3814-3822 (1996).
8. Stapleton A, Timme T, Gousse A et al.: Primary human prostate cancer cells harbouring p53 mutations are clonally expanded in metastases. Clin. Cancer Res. 3(8), 1389-1397 (1997).
9. Colletier PJ, Ashoori F, Cowen D et al.: Adenoviral-mediated p53 transgene expression sensitizes both wild type and null p53 prostate cancer cells in vitro to radiation. Int. J. Radiat. Oncol. Biol. Phys. 48 (5), 1507-1512 (2000).
10. Merritt JA, Roth JA, Logothetis CJ: Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin. Oncol. 28(5 Suppl. 16), 105-114 (2001).
11. Kirn D: Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of Phase I and II trials. Expert Opin. Biol. Ther. 1(3), 525-538 (2001).
12. Collis SJ, Khater K, DeWeese, TL: Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy. World J. Urol. 21(4), 275-289 (2003).
13. Lin E, Nemunaitis J: Oncolytic viral therapies. Cancer Gene Thmer. 11(10), 643-664 (2004).
14. Swisher SG, Roth JA, Komaki R et al.: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res. 9(1), 93-101 (2003).
15. DeWeese TL, van der Poel H, Li S et al.: A Phase I trial of CV706, a replicationcompetent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61(20), 7464-7472 (2001).
16. Lorence RM, Pecora AL, Major PP et al.: Overview of Phase I studies of intravenous administration of PV701, an oncolytic virus. Curr. Opin. Mol. Ther. 5(6), 618-624 (2003).
17. Zumstein L, Call D, Merritt J, Sobol RE, Menander, K: Safety of adenoviral vectors: results of clinical investigations in 445 cancer patients treated with Advexin® (Adenoviral p53) gene therapy in American Society of Cancer Gene Therapy Vol. Abstr. 1007, IN, USA (2004).
18. Nemunaitis J, Swisher SG, Timmons T et al.: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. 18(3), 609-622 (2000).
19. Fox JL: China approves first gene therapy. Nature Biotechnol. 22(1), 3-4 (2004).
20. Vokes EE, Weichelbaum RR, Lippman SM, Hong WK: Head and neck cancer. New Engl. J. Med. 328, 84-194 (1993).
21. Peng Z, Han D, Zhang S et al.: Clinical evaluation of safety and efficacy of intratumoral administration of a recombinant adenoviral-p53 anticancer agent (Genkaxin®). In The American Society of Gene Ther. Vol. 7(Suppl. 1), Verma IM (Ed), Molecular Therapy, Elsevier, Inc., Washington DC, USA, S422 (2003).
22. Sasaki R, Shirakawa T, Zhang ZJ et al.: Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 51(5), 1336-1345 (2001).
23. Clayman GL: The current status of gene therapy. Semin.Oncol. 27(4 Suppl. 8), 39-43 (2000).
24. Roth J, Cristiano R: Gene therapy for cancer: what have we done and where are we going? J. Natl Cancer Inst. 89(1), 21-39 (1997).
25. Clayman GL, Frank DK, Bruso PA, Goepfert H: Adenovirus-mediated wild type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin. Cancer Res. 5(7), 1715-1722 (1999).
26. Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL: Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother. Pharmacol. 44(2), 143-151 (1999).
27. Xi S, Grandis JR: Gene therapy for the treatment of oral squamous cell carcinoma. J. Dent. Res. 82(1), 11-16 (2003).
28. Clayman GL, el-Naggar AK, Lippman SM et al.: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16(6), 2221-2232 (1998).
29. Goodwin WJ, Esser D, Clayman GL, Al E: Randomized Phase II study of intratumoral injection of two dosing schedules using a replication-deficient adenovirus carrying the p53 gene (AD5CMV-P53) in patients with recurrent/refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol. 18, 445a (1999).
30. Heise C, Williams A, Olesch J, Kirn D: Efficacy of a replication- competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther. 6, 499-504 (1999).
31. Heise C, Ganly I, Kim YT et al.: Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther. 7(22), 1925-1929 (2000).
32. Ganly I, Kirn D, Eckhardt G et al.: A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. [Erratum appears in Clin. Cancer. Res. 6(5), 2120 (2000). Note: Eckhardt SG [corrected to Eckhardt G]. Clin. Cancer Res. 6(3), 798-806 (2000).
33. Nemunaitis J, Ganly I, Khuri F et al.: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res. 60(22), 6359-6366 (2000).
34. Nemunaitis J, Cunningham C, Tong AW et al.: Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther. 10(5), 341-352 (2003).
35. Heise C, Kirn, DH: Replication-selective adenoviruses as oncolytic agents. J. Clin. Invest. 105(7), 847-851 (2000).
36. Mymryk JS: Tumor suppressive properties of the adenovirus 5 E1A oncogene. Oncogene 13(8), 1581-1589 (1996).
37. Khuri FR, Nemunaitis J, Ganly I et al.: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5- fluorouracil in patients with recurrent head and neck cancer [see comment]. Nature Med. 6(8), 879-885 (2000).
38. Yoo GH, Hung MC, Lopez-Berestein G et al.: Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin. Cancer Research 7(5), 1237-1245 (2001).
39. Ueno NT, Bartholomeusz C, Xia W et al.: Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res. 62(22), 6712-6716 (2002).
40. Pecora AL, Rizvi N, Cohen GI et al.: Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers [see comment]. J. Clin. Oncol. 20(9), 2251-2266 (2002).
41. Yu DC, Chen Y, Dilley J et al.: Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 61(2), 517-525, (2001).
42. Freytag SO, Khil M, Stricker H et al.: Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62(17), 4968-4976 (2002).
43. Ogretmen B, Hannun YA: Biologically active sphingolipids in cancer pathogenesis and treatment. Nature Rev. Cancer 4(8), 604-616 (2004).
44. Seelan RS, Qian C, Yokomizo A et al.: Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chrom. Cancer 29(2), 137-146 (2000).
45. Mao CG, Xu RJ, Szulc ZM et al.: Cloning and characterization of a novel human alkaline ceramidase - a mammalian enzyme that hydrolyzes phytoceramide. J. Biol. Chem. 276(28), 26577-26588 (2001).
46. Koch J, Gartner S, Li CM et al.: Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification Of the first molecular lesion causing Farber disease. J. Biol. Chem. 271(51), 33110-33115 (1996).
47. El Bawab S, Bielawska A, Hannun YA: Purification and characterization of a membrane-bound nonlysosomal ceramidase from rat brain. J. Biol. Chem. 274(39), 27948-27955 (1999).
48. El Bawab S, Roddy P, Qian T et al.: Molecular cloning and characterization of a human mitochondrial ceramidase. J. Biol. Chem. 275(28), 21508-21513 (2000).
49. Dong JT: Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Met. Rev. 20(3-4), 173-193 (2001).
50. Lee MJ, Van Brocklyn JR, Thangada S et al.: Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 279(5356), 1552-1555 (1998).
51. Strelow A, Bernardo K, Adam-Klages S et al.: Overexpression of acid ceramidase protects from tumor necrosis factorinduced cell death. J. Exp. Med. 192(5), 601-612 (2000).
52. Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS: Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol.Ther. 2(4), 348-358 (2000).
53. Hyer ML, Sudarshan S, Kim Y et al.: Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fasmediated apoptosis. Cancer Biology Ther. 1(4), 348-358 (2002).
54. Norris JS, Hyer ML, Voelkel-Johnson C et al.: The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr. Gene Ther. 1(1), 123-136 (2001).
55. Norris JS, Holman DH, Hyer ML et al.: Ceramide, Ceramidase and FasL Gene Therapy in Prostate Cancer. In:Death Receptors in Cancer Therapy, Vol. El-Deiry WS (Ed.), Humana Press, Inc., NJ, USA (2004) In Press.
56. Holman DH, Hyer ML, El-Zawahry AM, Keller GM & Norris JS. Pro-apoptotic Strategy in Cancer Gene Therapy. In Cancer Gene Therapy (Eds.) Curiel DT, Douglas J Humana Press, Inc., NJ, USA (2003).
57. Hyer ML, Sudarshan S, Schwartz DA et al.: Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther. 10(4), 330-339 (2003).
58. Rubinchik S, Wang D, Yu H et al.: A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol. Ther. 4(5), 416-426 (2001).
59. Tatum EL: Molecular Biology, Nucleic Acids, and the Future of Medicine. In Reflections on Research and the Future of Medicine Lyght CE (Ed.), McGraw-Hill, NY, USA. 31-49 (1967).
60. Blaese RM, Culver KW Miller, AD et al.: T lymphocyte-directed gene therapy for ADASCID: initial trial results after 4 years. Science 270(5235), 475-480 (1995).
61. Hannun YA, Luberto C. Ceramide in the eukaryotic stress response. Trends Cell Biol. 10(2), 73-80 (2000).
62. Hannun YA: Functions of ceramide in coordinating cellular responses to stress. Science 274(5294) 1855-1859 (1996).
63. http://p53.curie.fr/p53%20site%20version%202.0/p53%20in%20cancer/ p53-databaseANAL.html (Accessed January 2005)
64. www.georgetown.edu/research/nrcbl/publications/scopenotes/sn24.htm (Accessed January 2005)